Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative join forces to combat vision loss from diabetes
12. November 2024 05:10 ET
|
Boehringer Ingelheim Limited
·More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of blindness in working-age adults. 1·DRD is a growing...
Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention
15. Oktober 2024 05:30 ET
|
Boehringer Ingelheim Limited
Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare...
Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide
08. Oktober 2024 02:35 ET
|
Boehringer Ingelheim
The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on...
Boehringer Ingelheim partners with NCD Alliance to target Non-Communicable Diseases in underserved communities
27. September 2024 06:05 ET
|
Boehringer Ingelheim
Boehringer Ingelheim has entered a partnership with the NCD Alliance, a network dedicated to shaping a world in which everyone can live a healthy and productive life, free from the preventable...
Boehringer Ingelheim expands cancer research at its Vienna site
25. September 2024 10:45 ET
|
Boehringer Ingelheim
Inauguration of Angelika Amon research building in Vienna Sustainable research building at a cost of EUR 60 million offers modern office and laboratory spaceOver the past five years, Boehringer’s...
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
16. September 2024 06:05 ET
|
Boehringer Ingelheim
Topline data from FIBRONEER™-IPF show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] at week 52...
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
09. September 2024 11:45 ET
|
Boehringer Ingelheim
Beamion LUNG-1, Phase Ib met its primary endpoint, demonstrating a meaningful objective response rate (ORR) of 66.7%, as assessed by blinded independent central review (BICR)1Preliminary activity in...
Boehringer Ingelheim announces plans to advance potential new treatment for Geographic Atrophy, following positive Phase I results
05. September 2024 10:52 ET
|
Boehringer Ingelheim
Ingelheim, Germany and Basel, Switzerland, September 5, 2024 – Boehringer Ingelheim and CDR-Life today announce positive results from the Phase I evaluation of BI 771716 (Study Record |...
Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio
03. September 2024 03:00 ET
|
Boehringer Ingelheim
INGELHEIM, Germany, September 03, 2024 – Boehringer Ingelheim today said it has acquired Saiba Animal Health AG, a company focused on the development of novel therapeutic medicines to address chronic...
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
27. August 2024 03:05 ET
|
Boehringer Ingelheim
Data from the phase Ib Beamion LUNG-1 trial selected for late-breaking oral presentation in the Presidential Symposium at WCLC on Monday, September 9. The U.S. FDA and China's CDE have granted...